Dr. Kayali is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Cattlemen Rd
Suite 200
Sarasota, FL 34232Phone+1 941-377-9993Fax+1 941-343-0026
Education & Training
- University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
- Trinity Health Oakland/Wayne State UniversityResidency, Internal Medicine, 2004 - 2007
- St Petersburg Medical State AcademyClass of 1997
Certifications & Licensure
- FL State Medical License 2010 - 2026
- OK State Medical License 2011 - 2012
- KY State Medical License 2007 - 2011
- MI State Medical License 2004 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2014
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Publications & Presentations
PubMed
- 224 citationsIncidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey.Paul D. Stein, Fadi Kayali, Ronald E. Olson
The Journal of Pediatrics. 2004-10-01 - 173 citationsVenous thromboembolism according to age: the impact of an aging population.Paul D. Stein, Russell D. Hull, Fadi Kayali, William A. Ghali, Andrew K. Alshab
Archives of Internal Medicine. 2004-11-08 - 264 citationsTwenty-one-year trends in the use of inferior vena cava filters.Paul D. Stein, Fadi Kayali, Ronald E. Olson
Archives of Internal Medicine. 2004-07-26
Journal Articles
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
Authored Content
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseOctober 2018
Other Languages
- Russian, Arabic, Russian, Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: